Folate-targeted immunotherapies: Passive and active strategies for cancer. (February 2019)

• Record Type: Journal Article
• Authors: Farran, Batoul; Pavitra, Eluri; Kasa, Prameswari; Peela, Sujatha; Rama Raju, Ganji Seeta; Nagaraju, Ganji Purnachandra
• Is Part Of: Cytokine & growth factor reviews. Volume 45(2019)
• Page Start: 45
• Page End: 52
• Publication Date: 2019-02
• Subjects: ACT adoptive cell transfer -- ADC antibody-drug conjugates -- ADCC antibody-dependent cell-mediated cytotoxicity -- BBB blood-brain-barrier -- CAR chimeric antigen receptor -- CART chimeric antigen receptor T cell therapy -- DNA deoxyribonucleic acid -- EGFR epithelial growth factor receptor -- EOC epithelial ovarian cancer -- FA folic acid -- FR folate receptor -- FRα folate receptor alpha -- hFRα human folate receptor alpha -- FRβ folate receptor beta -- IgE immunoglobulin E -- IgG immunoglobulin G -- mAB monoclonal antibody -- NSCLC non-small cell lung cancer -- NFKB nuclear factor kappa-light-chain-enhancer of activated B cells -- PD-1 programmed cell death protein 1 -- PTEN phosphatase and tensin homolog -- RCC renal cell carcinoma -- RNA ribonucleic acid -- SEERS surface-enhanced, resonance Raman scattering -- siRNA silencing RNA -- TAA tumor-associated antigens -- TAL tumor-associated lymphocyte -- TCB T cell bispecific antibody -- TLR toll-like receptors -- TNFα tumor necrosis factor alpha -- VEGF vascular endothelial growth factor; Folate receptor -- Immune therapy -- Targeted therapy -- Vaccines -- Solid cancers; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2019.02.001
• Languages: English
• ISSNs: 1359-6101

Abstract

Graphical abstract: Highlights: The transport protein FRα is upregulated in various solid malignancies. FRα is immunogenic and is a suitable target for immunotherapeutic drugs in cancer. Passive anti-FRα immunotherapies include monoclonal antibodies. Active anti-FRα immunotherapies include CART, folate-associated haptens and vaccines. Abstract: The glycoprotein FRα is a membrane-attached transport protein that is shielded from the immune system in healthy cells. However, it is upregulated in various malignancies, involved in cancer development and is also immunogenic. Furthermore, FRα is a tumor-associated antigen endowed with unique properties, thus rendering it a suitable target for immunotherapeutic development in cancer. Various anti- FRα immunotherapeutic strategies are thus currently being developed and clinically assessed for the treatment of various solid tumors. These approaches include passive anti-FRα immunotherapies, such as monoclonal antibodies, or active immunotherapies, such as CART, folate haptens and vaccines. In this review, we will explore the advances in the field of FRα-based immune therapies and discuss both their successes and shortcomings in the clinical setting.